Epigenetics in Cardiovascular Disease, a new volume in the Translational Epigenetics series, offers a comprehensive overview of the epigenetics mechanisms governing cardiovascular disease development, as well as instructions in research methods and guidance in pursing new studies. More than thirty international experts provide an (i) overview of the epigenetics mechanisms and their contribution to cardiovascular disease development, (i) high-throughput methods for RNA profiling including single-cell RNA-seq, (iii) the role of nucleic acid methylation in cardiovascular disease development, (iv) epigenetic actors as biomarkers and drug targets, (v) and the potential of epigenetics to advance personalized medicine. Here, readers will discover strategies to combat research challenges, improve quality of their epigenetic research and reproducibility of their findings. Additionally, discussion of assay and drug development for personalized healthcare pave the way for a new era of understanding in cardiovascular disease.
- Offers a thorough overview of role of epigenetics mechanisms in cardiovascular disease
- Includes guidance to improve research plans, experimental protocols design, quality and reproducibility of results in new epigenetics research
- Explores biomarkers and drug targets of therapeutic potential to advance personalized healthcare
- Features chapter contributions from a wide range of international researchers in the field
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
Dateigröße
ISBN-13
978-0-12-822259-1 (9780128222591)
Schweitzer Klassifikation
SECTION I INTRODUCTORY INFORMATION1. The ever-growing burden of cardiovascular disease2. Epigenetics concepts: An overview3. From classical signaling pathways to the nucleus
SECTION II EPIGENETICS MECHANISMS IN CARDIOVASCULAR DISEASE4. DNA methylation in heart failure5. Histone modifications in cardiovascular disease initiation and progression6. RNA modifications in cardiovascular disease-An experimental and computational perspective7. Regulatory RNAs in cardiovascular disease8. Regulation of splicing in cardiovascular disease9. Cardiac transcriptomic remodeling in metabolic syndrome10. Sex differences in epigenetics mechanisms of cardiovascular disease11. Epigenetics in cardiac development and human induced pluripotent stem cells
SECTION III BIOMARKER VALUE12. Peripheral blood DNA and RNA biomarkers of cardiovascular disease in clinical practice13. Epigenetics and physical exercise14. Long noncoding RNAs and circular RNAs as heart failure biomarkers15. Artificial intelligence in clinical decision-making for diagnosis of cardiovascular disease using epigenetics mechanisms
SECTION IV THERAPEUTIC POTENTIAL16. Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease
SECTION V METHODOLOGICAL ISSUES17. Single-cell RNA sequencing in cardiovascular science18. Good laboratory and experimental practices for microRNA analysis in cardiovascular research19. Analytical challenges in microRNA biomarker development: Best practices for analyzing microRNAs in cell-free biofluids20. Concept of biological reference materials for RNA analysis in cardiovascular disease21. Unbiased bioinformatics analysis of microRNA transcriptomics datasets and network theoretic target prediction
